Clinical development of panobinostat in classical Hodgkin’s lymphoma

References

• Taby R, Issa JP. Cancer epigenetics. CA Cancer J. Clin.60(6), 376–392 (2010).
   PubMed Web of Science ®Google Scholar
• Esteller M. Epigenetics in cancer. N. Engl. J. Med.358(11), 1148–1159 (2008).
   PubMed Web of Science ®Google Scholar
• Bhalla KN. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J. Clin. Oncol.23(17), 3971–3993 (2005).
   PubMed Web of Science ®Google Scholar
• Issa JP. DNA methylation as a therapeutic target in cancer. Clin. Cancer Res.13(6), 1634–1637 (2007).
   PubMed Web of Science ®Google Scholar
• Kuendgen A, Lubbert M. Current status of epigenetic treatment in myelodysplastic syndromes. Ann. Hematol.87(8), 601–611 (2008).
   PubMed Web of Science ®Google Scholar
• Singh BN, Zhang G, Hwa YL, Li J, Dowdy SC, Jiang SW. Nonhistone protein acetylation as cancer therapy targets. Expert Rev. Anticancer Ther.10(6), 935–954 (2010).
   PubMed Web of Science ®Google Scholar
• Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov.5(9), 769–784 (2006).
   PubMed Web of Science ®Google Scholar
• Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer6(1), 38–51 (2006).
   PubMed Web of Science ®Google Scholar
• Stimson L, Wood V, Khan O, Fotheringham S, La Thangue NB. HDAC inhibitor-based therapies and haematological malignancy. Ann. Oncol.20(8), 1293–1302 (2009).
   PubMed Web of Science ®Google Scholar
• Gloghini A, Buglio D, Khaskhely NM et al. Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors. Br. J. Haematol.147(4), 515–525 (2009).
   PubMed Web of Science ®Google Scholar
• Buglio D, Khaskhely NM, Voo KS, Martinez-Valdez H, Liu YJ, Younes A. HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma. Blood117(10), 2910–2917 (2011).
   PubMed Web of Science ®Google Scholar
• Banerjee D. Recent advances in the pathobiology of Hodgkin’s lymphoma: potential impact on diagnostic, predictive, and therapeutic strategies. Adv. Hematol.2011, 439456 (2011).
   PubMedGoogle Scholar
• Younes A, Bartlett NL, Leonard JP et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N. Engl. J. Med.363(19), 1812–1821 (2010).
   PubMed Web of Science ®Google Scholar
• Johnston PB, Ansell SM, Colgan JP et al. mTOR inhibition for relapsed or refractory hodgkin lymphoma: promising single agent activity with everolimus (RAD001). Blood110(11), (2007) (Abstract 2555).
   Google Scholar
• Boll B, Borchmann P, Topp MS et al. Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma. Br. J. Haematol.148(3), 480–482 (2010).
   PubMed Web of Science ®Google Scholar
• Sureda A, Younes A, Ben-Yehuda D et al. Final ANALYSIS: Phase II study of oral panobinostat in relapsed/refractory Hodgkin lymphoma patients following autologous hematopoietic stem-cell transplant. Blood116(21), (2010) (Abstract 419).
   Google Scholar
• Younes A, Bociek RG, Kuruvilla J et al. Mocetinostat (MGCD0103), an isotype-selective histone deacetylase (HDAC) inhibitor, produces clinical responses in relapsed/refractory hodgkin lymphoma (HL): update from a Phase II clinical study. Blood116(21), (2010) (Abstract 1763).
   Google Scholar
• Younes A, Hernandez F, Bociek RG et al. ENGAGE- 501: Phase 2 Study investigating the role of epigenetic therapy with entinostat (SNDX-275) In relapsed and refractory Hodgkin’s lymphoma (HL), interim results. Blood116(21), (2010) (Abstract 3959).
   Google Scholar
• Kirschbaum MH, Goldman BH, Zain JM et al. Vorinostat (suberoylanilide hydroxamic acid) in relapsed or refractory Hodgkin lymphoma: SWOG 0517. Blood110(11), (2007) (Abstract 2574).
   Google Scholar
• Lemoine M, Buglio D, Jona A et al. The pan-deacetylase inhibitor panobinostat downregulates HIF-1 α and VEGF and, synergizes with everolimus in Hodgkin lymphoma cell lines. Blood116(21), (2010) (Abstract 2851).
   PubMedGoogle Scholar
• Younes A. Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma. Hematology Am. Soc. Hematol. Educ. Program.2009, 507–519 (2009).
   Google Scholar
• Kato N, Fujimoto H, Yoda A et al. Regulation of Chk2 gene expression in lymphoid malignancies: involvement of epigenetic mechanisms in Hodgkin’s lymphoma cell lines. Cell Death Differ.11(Suppl. 2), S153–S161 (2004).
   Google Scholar
• Buglio D, Georgakis GV, Hanabuchi S et al. Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines. Blood112(4), 1424–1433 (2008).
   PubMed Web of Science ®Google Scholar
• Martin-Sanchez E, Sanchez-Beato M, Rodriguez ME et al. HDAC inhibitors induce cell-cycle arrest, activate the apoptotic extrinsic pathway and synergize with a novel PIM inhibitor in Hodgkin lymphoma-derived cell lines. Br. J. Haematol.152(3), 352–356 (2011).
   PubMed Web of Science ®Google Scholar
• Hartlapp I, Pallasch C, Weibert G, Kemkers A, Hummel M, Re D. Depsipeptide induces cell death in Hodgkin lymphoma-derived cell lines. Leuk. Res.33(7), 929–936 (2009).
   PubMed Web of Science ®Google Scholar
• Jona A, Khaskhely N, Buglio D et al. The histone deacetylase inhibitor entinostat (SNDX-275) targets Hodgkin lymphoma through a dual mechanism of immune modulation and apoptosis induction. Blood116(21), (2010) (Abstract 2850).
   Google Scholar
• DeAngelo D, Spencer A, Ottmann OG et al. Panobinostat has activity in treatment-refractory Hodgkin lymphoma. Haematologica94(Suppl. 2), 205 (2009) (Abstract 0505).
   PubMedGoogle Scholar
• Dickinson M, Ritchie D, DeAngelo DJ et al. Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin lymphoma. Br. J. Haematol.147(1), 97–101 (2009).
   PubMed Web of Science ®Google Scholar
• Ellis L, Pan Y, Smyth GK et al. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin. Cancer Res.14(14), 4500–4510 (2008).
   PubMed Web of Science ®Google Scholar
• Younes A, Copeland A, Fanale MA et al. Phase I/II study of the novel combination of panobinostat (LBH589) and everolimus (RAD001) in relapsed/refractory Hodgkin and non-Hodgkin lymphoma. Blood116(21), (2010) (Abstract 3964).
   Google Scholar
• Duvic M, Talpur R, Ni X et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood109(1), 31–39 (2007).
   PubMed Web of Science ®Google Scholar
• Olsen EA, Kim YH, Kuzel TM et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J. Clin. Oncol.25(21), 3109–3115 (2007).
   PubMed Web of Science ®Google Scholar
• Kirschbaum M, Popplewell L, Nademanee AP et al. A Phase 2 study of vorinostat (suberoylanilide hydroxamic acid, SAHA) in relapsed or refractory indolent non-Hodgkin’s lymphoma. A California Cancer Consortium Study. Blood112(11), (2008) (Abstract 1564).
   Google Scholar
• Crump M, Coiffier B, Jacobsen ED et al. Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. Ann. Oncol.19(5), 964–969 (2008).
   PubMed Web of Science ®Google Scholar
• Younes A, Wedgwood A, McLaughlin P et al. Treatment of relapsed or refractory lymphoma with the oral isotype-selective histone deacetylase inhibitor MGCD0103: interim results from a Phase II study. Blood110(11), (2007) (Abstract 2571).
   PubMedGoogle Scholar
• Wardell SE, Ilkayeva OR, Wieman HL et al. Glucose metabolism as a target of histone deacetylase inhibitors. Mol. Endocrinol.23(3), 388–401 (2009).
   PubMed Web of Science ®Google Scholar
• Atadja P. Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. Cancer Lett.280(2), 233–241 (2009).
   PubMed Web of Science ®Google Scholar
• Duvic M, Becker JC, Dalle S et al. Phase II trial of oral panobinostat (LBH589) in patients with refractory cutaneous T-cell lymphoma (CTCL). ASH Annual Meeting Abstracts112(11), 1005 (2008).
   Google Scholar